LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 131

Search options

  1. Article: Mécanisme d’interférence à l’ARN vis-à-vis du virus de l’hépatite B in vivo chez la souris transgénique.

    Chevaliez, Stéphane

    Virologie (Montrouge, France)

    2021  Volume 9, Issue 1, Page(s) 70

    Title translation Clearance of hepatitis B from the liver of transgenic mice by short hairpin RNAs.
    Language French
    Publishing date 2021-08-25
    Publishing country France
    Document type Journal Article
    ZDB-ID 2118387-9
    ISSN 1950-6961 ; 1267-8694
    ISSN (online) 1950-6961
    ISSN 1267-8694
    DOI 10.1684/vir.2020.1289
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Strategies for the improvement of HCV testing and diagnosis.

    Chevaliez, Stéphane

    Expert review of anti-infective therapy

    2019  Volume 17, Issue 5, Page(s) 341–347

    Abstract: ... ...

    Abstract Introduction
    MeSH term(s) Dried Blood Spot Testing ; Hepatitis B Surface Antigens/blood ; Hepatitis C/diagnosis ; Hepatitis C/virology ; Humans ; Mass Screening/methods ; Point-of-Care Testing
    Chemical Substances Hepatitis B Surface Antigens
    Language English
    Publishing date 2019-04-22
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2181279-2
    ISSN 1744-8336 ; 1478-7210
    ISSN (online) 1744-8336
    ISSN 1478-7210
    DOI 10.1080/14787210.2019.1604221
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6106: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: New markers for diagnosis and management of chronic hepatitis C virus infection.

    Chevaliez, Stephane

    Annals of gastroenterology

    2014  Volume 26, Issue 2, Page(s) 98–99

    Language English
    Publishing date 2014-04-08
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 2032850-3
    ISSN 1108-7471
    ISSN 1108-7471
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2455: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Dried blood spot sampling for hepatitis C virus infection: A new tool to simplify testing algorithms.

    Garrigou, Olivia / Ortonne, Valérie / Soulier, Alexandre / Chevaliez, Stéphane

    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

    2021  Volume 141, Page(s) 104876

    MeSH term(s) Algorithms ; Dried Blood Spot Testing ; Hepacivirus/genetics ; Hepatitis C/diagnosis ; Humans
    Language English
    Publishing date 2021-06-03
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 1446080-4
    ISSN 1873-5967 ; 1386-6532
    ISSN (online) 1873-5967
    ISSN 1386-6532
    DOI 10.1016/j.jcv.2021.104876
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3790: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Is HBsAg quantification ready, for prime time?

    Chevaliez, Stéphane

    Clinics and research in hepatology and gastroenterology

    2013  Volume 37, Issue 6, Page(s) 559–563

    Abstract: Despite the availability of an efficient hepatitis B vaccine, approximately 240 million individuals are chronically infected with hepatitis B virus worldwide. One-fourth of hepatitis B surface antigen (HBsAg)-positive patients will develop complications, ...

    Abstract Despite the availability of an efficient hepatitis B vaccine, approximately 240 million individuals are chronically infected with hepatitis B virus worldwide. One-fourth of hepatitis B surface antigen (HBsAg)-positive patients will develop complications, such as cirrhosis or hepatocellular carcinoma, both major causes of liver-related deaths. Antiviral therapies, such as pegylated interferon alpha or nucleoside/nucleotide analogues, are effective in suppressing HBV DNA and reducing the subsequent risk of fibrosis progression, cirrhosis and hepatocellular carcinoma. HBsAg has proven to be a steady, reliable marker of chronic HBV carriage that can also be used to predict clinical outcomes. Three commercial enzyme immunoassays are now available for HBsAg quantification. A number of recent studies have shown clinical utility of HBsAg quantification in combination with HBV DNA levels to identify inactive carriers who need antiviral therapy and in interferon treated-patients in order to predict the virological response to pegylated interferon alpha.
    MeSH term(s) Antiviral Agents/therapeutic use ; Biomarkers/blood ; DNA, Viral/blood ; HIV Infections/complications ; Hepatitis B Surface Antigens/blood ; Hepatitis B virus/genetics ; Hepatitis B virus/immunology ; Hepatitis B, Chronic/blood ; Hepatitis B, Chronic/complications ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy ; Hepatitis D, Chronic/complications ; Humans ; Interferon-alpha/therapeutic use ; Nucleosides/therapeutic use ; Nucleotides/therapeutic use ; Polyethylene Glycols/therapeutic use ; Recombinant Proteins/therapeutic use
    Chemical Substances Antiviral Agents ; Biomarkers ; DNA, Viral ; Hepatitis B Surface Antigens ; Interferon-alpha ; Nucleosides ; Nucleotides ; Recombinant Proteins ; Polyethylene Glycols (30IQX730WE) ; peginterferon alfa-2b (G8RGG88B68) ; peginterferon alfa-2a (Q46947FE7K)
    Language English
    Publishing date 2013-12
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 2594333-9
    ISSN 2210-741X ; 2210-7401
    ISSN (online) 2210-741X
    ISSN 2210-7401
    DOI 10.1016/j.clinre.2013.07.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings.

    Chevaliez, Stéphane / Pawlotsky, Jean-Michel

    Journal of hepatology

    2018  Volume 69, Issue 4, Page(s) 916–926

    Abstract: Worldwide, the increasingly dominant model of laboratory testing is the centralised laboratory, in which automation of analytical processes increases, enabling the analysis of large numbers of samples at a relatively low cost. However, this trend does ... ...

    Abstract Worldwide, the increasingly dominant model of laboratory testing is the centralised laboratory, in which automation of analytical processes increases, enabling the analysis of large numbers of samples at a relatively low cost. However, this trend does not fulfil the requirements for care of patients with chronic hepatitis B and C in resource-limited settings. Alternative models using point-of-care (POC) tests and dried blood spots (DBSs) are increasingly being considered for viral hepatitis screening, diagnosis and monitoring. POC tests are small devices providing qualitative and/or quantitative determination of viral antibodies and/or antigens. They can use original specimen matrices, such as oral fluid or blood collected from a fingerstick. POC tests are particularly useful for large-scale screening, and to improve access to care in regions where laboratory access is limited. New POC devices that detect and quantify viral nucleic acids are at the developmental stage. DBSs offer the main advantage of enabling storage of desiccated blood that can be easily transported to reference centres, where state-of-the-art molecular and serological diagnostic tests are available. However, standardisation and better automation of DBS handling are needed. Herein, we review alternatives to classical hepatitis B and C virological tests, examining POC tests and DBSs, as well as alternatives to nucleic acid testing. Innovations in testing approaches resulting from the availability of these new assays are also discussed.
    MeSH term(s) Dried Blood Spot Testing ; Health Resources ; Hepatitis B/diagnosis ; Hepatitis B/virology ; Hepatitis B Antibodies/blood ; Hepatitis B Surface Antigens/blood ; Hepatitis C/diagnosis ; Hepatitis C/virology ; Hepatitis C Antibodies/blood ; Humans ; Point-of-Care Systems ; RNA, Viral/blood ; Serologic Tests
    Chemical Substances Hepatitis B Antibodies ; Hepatitis B Surface Antigens ; Hepatitis C Antibodies ; RNA, Viral
    Language English
    Publishing date 2018-05-23
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2018.05.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2027: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.

    Chevaliez, Stéphane

    Clinics and research in hepatology and gastroenterology

    2011  Volume 35 Suppl 2, Page(s) S46–51

    Abstract: The treatment of chronic hepatitis C virus (HCV) infection has substantially evolved over the past decade, following the Consensus Conference organized by the European Association for the Study of the Liver in 1999. Since then, the standard of care (SoC) ...

    Abstract The treatment of chronic hepatitis C virus (HCV) infection has substantially evolved over the past decade, following the Consensus Conference organized by the European Association for the Study of the Liver in 1999. Since then, the standard of care (SoC) for patients with chronic hepatitis C has been the combination of pegylated interferon (pegIFN) alpha-2a or -2b and ribavirin. In patients infected with HCV genotype 1, by far the most frequent HCV genotype worldwide, such treatment leads to a cure of infection in only 40-50% of cases. After a decade in which pegIFN alpha and ribavirin therapy was the only available option, triple therapy with HCV protease inhibitors (PIs; boceprevir and telaprevir) in combination with pegIFN alpha and ribavirin has become the new SoC for genotype-1-infected patients. With PI therapy, higher cure rates can be achieved, but specific issues are also raised, such as the emergence of resistance to PIs. For this reason, the present report examines the antiviral activity of PIs and what is currently known about resistance to them, while focusing on telaprevir and boceprevir, two HCV PIs recently licensed for the treatment of treatment-naïve and treatment-experienced genotype-1 patients with chronic hepatitis C. The clinical relevance of resistance testing is also discussed.
    MeSH term(s) Antiviral Agents/therapeutic use ; Drug Resistance, Viral ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/virology ; Humans ; Protease Inhibitors/therapeutic use
    Chemical Substances Antiviral Agents ; Protease Inhibitors
    Language English
    Publishing date 2011-12
    Publishing country France
    Document type Journal Article
    ZDB-ID 2594333-9
    ISSN 2210-741X ; 2210-7401
    ISSN (online) 2210-741X
    ISSN 2210-7401
    DOI 10.1016/S2210-7401(11)70007-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.

    Vo-Quang, Erwan / Soulier, Alexandre / Ndebi, Mélissa / Rodriguez, Christophe / Chevaliez, Stéphane / Leroy, Vincent / Fourati, Slim / Pawlotsky, Jean-Michel

    Hepatology (Baltimore, Md.)

    2023  Volume 78, Issue 2, Page(s) 607–620

    Abstract: Background and aims: Suboptimal rates of sustained virological response have been reported in patients infected with an "unusual," non-1a/1b HCV genotype 1 subtype. The objectives of this study were to assess the proportion of non-1a/1b genotype 1 ... ...

    Abstract Background and aims: Suboptimal rates of sustained virological response have been reported in patients infected with an "unusual," non-1a/1b HCV genotype 1 subtype. The objectives of this study were to assess the proportion of non-1a/1b genotype 1 subtypes in a population of HCV-infected patients who failed to achieve sustained virological response after first-line direct-acting antiviral treatment, to virologically characterize their failures and to assess their outcomes on retreatment.
    Approach and results: Samples addressed between January 2015 and December 2021 to the French National Reference Center for Viral Hepatitis B, C, and D were prospectively analyzed by means of Sanger and deep sequencing. Among 640 failures, 47 (7.3%) occurred in patients infected with an "unusual" genotype 1 subtype. Samples were available in 43 of them; 92.5% of these patients were born in Africa. Our results show the presence at baseline and at treatment failure of NS3 protease and/or NS5A polymorphisms conferring inherent reduced susceptibility to direct-acting antivirals in these patients, together with the presence at failure of additional resistance-associated substitutions not naturally present as dominant species, but jointly selected by first-line therapy.
    Conclusions: Patients infected with "unusual" HCV genotype 1 subtypes are over-represented among direct-acting antiviral treatment failures. Most of them were born and likely infected in sub-Saharan Africa. "Unusual" HCV genotype 1 subtypes naturally carry polymorphisms that confer reduced susceptibility to the drugs currently used to cure hepatitis C, in particular the NS5A inhibitors. Retreatment with sofosbuvir plus an NS3 protease and an NS5A inhibitor is generally efficacious.
    MeSH term(s) Humans ; Antiviral Agents ; Hepatitis C, Chronic/drug therapy ; Genotype ; Drug Therapy, Combination ; Drug Resistance, Viral/genetics ; Viral Nonstructural Proteins/genetics ; Hepacivirus/genetics ; Treatment Failure ; Hepatitis C/drug therapy ; Hepatitis C/epidemiology ; Retreatment ; Peptide Hydrolases/genetics ; Peptide Hydrolases/therapeutic use
    Chemical Substances Antiviral Agents ; Viral Nonstructural Proteins ; Peptide Hydrolases (EC 3.4.-)
    Language English
    Publishing date 2023-04-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604603-4
    ISSN 1527-3350 ; 0270-9139
    ISSN (online) 1527-3350
    ISSN 0270-9139
    DOI 10.1097/HEP.0000000000000379
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1660: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Performance of rapid diagnostic tests for HCV infection in serum or plasma.

    Chevaliez, Stéphane / Roudot-Thoraval, Françoise / Hézode, Christophe / Pawlotsky, Jean-Michel / Njouom, Richard

    Future microbiology

    2021  Volume 16, Page(s) 713–719

    Abstract: Aim: ...

    Abstract Aim:
    MeSH term(s) Cameroon ; Diagnostic Tests, Routine/methods ; France ; Hepatitis C/diagnosis ; Humans ; Mass Screening/methods ; Sensitivity and Specificity
    Language English
    Publishing date 2021-07-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2254620-0
    ISSN 1746-0921 ; 1746-0913
    ISSN (online) 1746-0921
    ISSN 1746-0913
    DOI 10.2217/fmb-2020-0295
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Performance of rapid diagnostic tests for hepatitis B surface antigen detection in serum or plasma.

    Chevaliez, Stéphane / Roudot-Thoraval, Françoise / Hézode, Christophe / Pawlotsky, Jean-Michel / Njouom, Richard

    Diagnostic microbiology and infectious disease

    2021  Volume 100, Issue 2, Page(s) 115353

    Abstract: Hepatitis B surface antigen (HBsAg) is a key marker for screening and laboratory diagnosis of HBV infection. Rapid diagnostic tests (RDTs) represent promising alternatives to immunoassay-based methods because they are simple, fast and cheap. These tests, ...

    Abstract Hepatitis B surface antigen (HBsAg) is a key marker for screening and laboratory diagnosis of HBV infection. Rapid diagnostic tests (RDTs) represent promising alternatives to immunoassay-based methods because they are simple, fast and cheap. These tests, therefore, represent a powerful tool for large-scale screening and diagnosis of HBV infection in the clinical setting. Performance of 6 RDTs have been assessed in a large series of serum or plasma samples (n = 501) collected in France and in Cameroon. Specificity varied from 98.0% to 99.5%, while clinical sensitivity, compared to immunoassays as the reference, was excellent for all six RDTs (98.3%-99.3%). The VIKIA HBsAg and First Response
    MeSH term(s) Cameroon/epidemiology ; Case-Control Studies ; Diagnostic Tests, Routine/methods ; France/epidemiology ; Hepatitis B/blood ; Hepatitis B/diagnosis ; Hepatitis B/epidemiology ; Hepatitis B Surface Antigens/blood ; Humans ; Immunoenzyme Techniques ; Sensitivity and Specificity ; Serologic Tests/methods
    Chemical Substances Hepatitis B Surface Antigens
    Language English
    Publishing date 2021-02-17
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 604920-5
    ISSN 1879-0070 ; 0732-8893
    ISSN (online) 1879-0070
    ISSN 0732-8893
    DOI 10.1016/j.diagmicrobio.2021.115353
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top